MA53351A - Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations - Google Patents
Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisationsInfo
- Publication number
- MA53351A MA53351A MA053351A MA53351A MA53351A MA 53351 A MA53351 A MA 53351A MA 053351 A MA053351 A MA 053351A MA 53351 A MA53351 A MA 53351A MA 53351 A MA53351 A MA 53351A
- Authority
- MA
- Morocco
- Prior art keywords
- heteroaromatic
- modulators
- nmda receptors
- nmda
- receptors
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862714100P | 2018-08-03 | 2018-08-03 | |
PCT/US2019/044814 WO2020086136A2 (fr) | 2018-08-03 | 2019-08-02 | Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
MA53351A true MA53351A (fr) | 2022-01-12 |
MA53351B1 MA53351B1 (fr) | 2023-08-31 |
Family
ID=69228330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53351A MA53351B1 (fr) | 2018-08-03 | 2019-08-02 | Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations |
Country Status (37)
Country | Link |
---|---|
US (4) | US10584131B2 (fr) |
EP (2) | EP4223760A1 (fr) |
JP (1) | JP7319369B2 (fr) |
KR (1) | KR20210039432A (fr) |
CN (1) | CN112513047B (fr) |
AR (1) | AR115905A1 (fr) |
AU (1) | AU2019368147B2 (fr) |
BR (1) | BR112021001967A2 (fr) |
CA (1) | CA3108519A1 (fr) |
CL (1) | CL2021000294A1 (fr) |
CO (1) | CO2021002898A2 (fr) |
CR (1) | CR20210125A (fr) |
CU (1) | CU24647B1 (fr) |
CY (1) | CY1126144T1 (fr) |
DK (1) | DK3830092T3 (fr) |
DO (1) | DOP2021000025A (fr) |
EA (1) | EA202190431A1 (fr) |
EC (1) | ECSP21014902A (fr) |
ES (1) | ES2951872T3 (fr) |
FI (1) | FI3830092T3 (fr) |
HR (1) | HRP20230774T1 (fr) |
HU (1) | HUE062566T2 (fr) |
IL (1) | IL280474B2 (fr) |
JO (1) | JOP20210020A1 (fr) |
LT (1) | LT3830092T (fr) |
MA (1) | MA53351B1 (fr) |
MX (1) | MX2021001367A (fr) |
PE (1) | PE20210948A1 (fr) |
PH (1) | PH12021550242A1 (fr) |
PL (1) | PL3830092T3 (fr) |
PT (1) | PT3830092T (fr) |
RS (1) | RS64359B1 (fr) |
SG (1) | SG11202101125VA (fr) |
SI (1) | SI3830092T1 (fr) |
TW (1) | TWI833783B (fr) |
WO (1) | WO2020086136A2 (fr) |
ZA (1) | ZA202101273B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4006038A1 (fr) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Modulateurs des récepteurs nmda à base de thiénopyrimidinone et leurs utilisations |
JP7071917B2 (ja) * | 2015-12-09 | 2022-05-19 | カデント セラピューティクス,インコーポレーテッド | ヘテロ芳香族nmda受容体モジュレーターおよびその使用 |
JP7332472B2 (ja) | 2016-12-22 | 2023-08-23 | ノバルティス アーゲー | Nmda受容体モジュレーターおよびその使用 |
CN112513047B (zh) | 2018-08-03 | 2023-10-20 | 诺华股份有限公司 | 芳香杂环nmda受体调节剂及其用途 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1067079A (fr) | 1976-07-22 | 1979-11-27 | Yamanouchi Pharmaceutical Co. | Composes heterobicycliques azotes |
FR2549834B1 (fr) | 1983-07-25 | 1985-10-18 | Sanofi Sa | Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques |
US4921854A (en) | 1986-12-30 | 1990-05-01 | Egis Gyogyszergyar | Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds |
US5298502A (en) | 1988-12-12 | 1994-03-29 | Fmc Corporation | Method and composition for photodynamic treatment and detection of tumors |
AU6643694A (en) | 1993-05-21 | 1994-12-20 | Pentapharm Ag | 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones |
CA2257950A1 (fr) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Promedicaments antagonistes de recepteurs de fibrinogenes |
US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
JP2004501901A (ja) | 2000-06-26 | 2004-01-22 | メルク エンド カムパニー インコーポレーテッド | イミノピリミジン系nmdanr2b受容体拮抗薬 |
US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
AR038118A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
MX2007000468A (es) | 2004-07-13 | 2007-03-08 | Hoffmann La Roche | Derivados de sulfonamida. |
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
US7906504B2 (en) | 2006-09-11 | 2011-03-15 | N.V. Organon | 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivatives |
EP2069315B1 (fr) | 2006-09-11 | 2011-09-07 | N.V. Organon | Derives d'acetamide de quinazolinone et d'isoquinolinone |
WO2008076883A2 (fr) | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Dérivés de triazine et leurs applications thérapeutiques |
EP1939187A1 (fr) | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Dérivés de pyridopyrimidone hétéroaryle substitués |
JP2010518080A (ja) | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療薬 |
EP2160389B1 (fr) | 2007-04-18 | 2014-03-12 | Probiodrug AG | Derivatives de thioxoquinazolinone en tant qu`inhibiteurs de la glutaminyl cyclase |
WO2008138126A1 (fr) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Dérivés bicycliques de pyrimidine en tant que bloqueurs des canaux calciques |
EP2190428A4 (fr) | 2007-08-21 | 2012-02-29 | Merck Sharp & Dohme | Composés hétérocycliques en tant qu'inhibiteurs de dipeptidylpeptidase-iv pour le traitement ou la prévention des diabètes |
TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
SG190603A1 (en) | 2008-05-01 | 2013-06-28 | Sirtris Pharmaceuticals Inc | Quinolines and related analogs as sirtuin modulators |
KR20110019385A (ko) | 2008-05-29 | 2011-02-25 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 이미다조피리딘 및 관련 유사체 |
EP2138494A1 (fr) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Dérivés substitués d'alkyl pyrimidin-4-one |
EP2315763B1 (fr) | 2008-07-03 | 2016-06-01 | Glaxosmithkline LLC | Benzimidazoles et analogues associés en tant que modulateurs de sirtuine |
CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
EP2342188B1 (fr) | 2008-09-29 | 2014-07-30 | GlaxoSmithKline LLC | Analogues de chroménone en tant que modulateurs de sirtuine |
BRPI1006128A2 (pt) | 2009-01-12 | 2016-11-01 | Cagen Inc | derivados de sulfonamida |
US8288428B2 (en) | 2009-03-27 | 2012-10-16 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
EP2264035A1 (fr) | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | B antagonistes de la glycine |
TW201116532A (en) | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
JP2013507417A (ja) | 2009-10-13 | 2013-03-04 | エム・エス・ディー・オス・ベー・フェー | アセチルコリン受容体に関連する疾患の処置のための縮合アジン誘導体 |
WO2011117382A1 (fr) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
EP2552905B1 (fr) | 2010-03-26 | 2016-10-05 | Boehringer Ingelheim International GmbH | Inhibiteurs de la kinase B-Raf |
CA2805724A1 (fr) | 2010-07-16 | 2012-01-19 | Rockefeller University | Oxadiazolo[3,2-a]pyrimidines et thiadiazolo[3,2-a]pyrimidines |
EP2630136A1 (fr) | 2010-10-21 | 2013-08-28 | Universität des Saarlandes | Inhibiteurs sélectifs de cyp11b1 pour le traitement de maladies dépendantes du cortisol |
US20120165330A1 (en) | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
WO2012129562A2 (fr) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Composés et procédés pour l'induction de la chondrogenèse |
CA2834164A1 (fr) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Benzoxazinones fusionnees comme modulateurs de canal ionique |
US9493412B2 (en) | 2011-09-27 | 2016-11-15 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
WO2013048942A1 (fr) | 2011-09-30 | 2013-04-04 | Bristol-Myers Squibb Company | Inhibiteurs quinoléinone carboxamide de lipase endothéliale |
US8993557B2 (en) | 2011-09-30 | 2015-03-31 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
CN102336768A (zh) | 2011-10-24 | 2012-02-01 | 中国科学院上海有机化学研究所 | N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途 |
SI2776038T1 (en) | 2011-11-11 | 2018-06-29 | Gilead Apollo, Llc | ACC INHIBITORS AND THEIR USE |
EA029542B1 (ru) | 2012-02-10 | 2018-04-30 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ |
WO2014066743A1 (fr) | 2012-10-25 | 2014-05-01 | Bioenergenix | Composés hétérocycliques pour l'inhibition de pask |
WO2014139144A1 (fr) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Composés et compositions thérapeutiques |
WO2014179144A1 (fr) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Composés hétérocycliques fongicides |
KR102272606B1 (ko) | 2013-06-28 | 2021-07-05 | 베이진 엘티디 | Raf 키나아제 및/또는 raf 키나아제 이량체 저해제로서 융합 트리시클릭 우레아 화합물 |
WO2015007453A1 (fr) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Dérivés hétérobicycliques microbiocides |
AR097795A1 (es) | 2013-09-26 | 2016-04-13 | Mnemosyne Pharmaceuticals Inc | Derivados de n-arilmetilo sulfonamida como moduladores negativos de nr2a |
PT3055315T (pt) | 2013-10-11 | 2018-10-25 | Hoffmann La Roche | Tiazolopirimidonas enquanto moduladores da atividade do recetor nmda |
WO2015064714A1 (fr) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | Dérivé substitué en position 1 d'imidazopyrimidinone ayant une activité inhibitrice sur l'autotaxine |
CN103664877A (zh) | 2013-12-25 | 2014-03-26 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
EP3191459A1 (fr) | 2014-09-05 | 2017-07-19 | AbbVie Deutschland GmbH & Co. KG | Composés hétérocycliques ou carbocycliques condensés portant un radical cycloaliphatique substitué et leur utilisation pour traiter les maladies liées à la vasopressine |
US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
UA120647C2 (uk) | 2015-04-15 | 2020-01-10 | Ф. Хоффманн-Ля Рош Аг | Піридопіримідинони та їх застосування як модуляторів рецептора n-метил-d-аспартату |
WO2017066590A1 (fr) | 2015-10-16 | 2017-04-20 | Northwestern University | Combinaison pharmaceutique d'un antipsychotique atypique et d'un modulateur de nmda pour le traitement de la schizophrénie, d'un trouble bipolaire, d'un trouble cognitif et d'un trouble dépressif majeur |
JP7071917B2 (ja) | 2015-12-09 | 2022-05-19 | カデント セラピューティクス,インコーポレーテッド | ヘテロ芳香族nmda受容体モジュレーターおよびその使用 |
EP4006038A1 (fr) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Modulateurs des récepteurs nmda à base de thiénopyrimidinone et leurs utilisations |
WO2017188694A1 (fr) | 2016-04-25 | 2017-11-02 | 이뮤노메트테라퓨틱스 인코포레이티드 | Composé hétéroaryle comprenant de l'azote et son utilisation |
WO2018026371A1 (fr) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Inhibiteurs doubles de nav1.2/5ht2a pour traiter des troubles du snc |
JP7332472B2 (ja) | 2016-12-22 | 2023-08-23 | ノバルティス アーゲー | Nmda受容体モジュレーターおよびその使用 |
CN111386273B (zh) | 2017-09-27 | 2024-06-14 | 因赛特公司 | 可用作tam抑制剂的吡咯并三嗪衍生物的盐 |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
CN112513047B (zh) | 2018-08-03 | 2023-10-20 | 诺华股份有限公司 | 芳香杂环nmda受体调节剂及其用途 |
-
2019
- 2019-08-02 CN CN201980051645.9A patent/CN112513047B/zh active Active
- 2019-08-02 EA EA202190431A patent/EA202190431A1/ru unknown
- 2019-08-02 AU AU2019368147A patent/AU2019368147B2/en active Active
- 2019-08-02 WO PCT/US2019/044814 patent/WO2020086136A2/fr active Application Filing
- 2019-08-02 PT PT198760258T patent/PT3830092T/pt unknown
- 2019-08-02 DK DK19876025.8T patent/DK3830092T3/da active
- 2019-08-02 TW TW108127473A patent/TWI833783B/zh active
- 2019-08-02 SG SG11202101125VA patent/SG11202101125VA/en unknown
- 2019-08-02 CA CA3108519A patent/CA3108519A1/fr active Pending
- 2019-08-02 RS RS20230563A patent/RS64359B1/sr unknown
- 2019-08-02 HU HUE19876025A patent/HUE062566T2/hu unknown
- 2019-08-02 IL IL280474A patent/IL280474B2/en unknown
- 2019-08-02 JP JP2021529249A patent/JP7319369B2/ja active Active
- 2019-08-02 ES ES19876025T patent/ES2951872T3/es active Active
- 2019-08-02 MX MX2021001367A patent/MX2021001367A/es unknown
- 2019-08-02 AR ARP190102209A patent/AR115905A1/es unknown
- 2019-08-02 HR HRP20230774TT patent/HRP20230774T1/hr unknown
- 2019-08-02 MA MA53351A patent/MA53351B1/fr unknown
- 2019-08-02 LT LTEPPCT/US2019/044814T patent/LT3830092T/lt unknown
- 2019-08-02 CU CU2021000013A patent/CU24647B1/es unknown
- 2019-08-02 PE PE2021000151A patent/PE20210948A1/es unknown
- 2019-08-02 EP EP23165151.4A patent/EP4223760A1/fr active Pending
- 2019-08-02 SI SI201930580T patent/SI3830092T1/sl unknown
- 2019-08-02 US US16/530,274 patent/US10584131B2/en active Active
- 2019-08-02 FI FIEP19876025.8T patent/FI3830092T3/fi active
- 2019-08-02 JO JOP/2021/0020A patent/JOP20210020A1/ar unknown
- 2019-08-02 CR CR20210125A patent/CR20210125A/es unknown
- 2019-08-02 BR BR112021001967-7A patent/BR112021001967A2/pt unknown
- 2019-08-02 KR KR1020217006300A patent/KR20210039432A/ko active Search and Examination
- 2019-08-02 PL PL19876025.8T patent/PL3830092T3/pl unknown
- 2019-08-02 EP EP19876025.8A patent/EP3830092B1/fr active Active
- 2019-11-08 US US16/678,806 patent/US10752633B2/en active Active
-
2021
- 2021-02-01 PH PH12021550242A patent/PH12021550242A1/en unknown
- 2021-02-02 DO DO2021000025A patent/DOP2021000025A/es unknown
- 2021-02-03 CL CL2021000294A patent/CL2021000294A1/es unknown
- 2021-02-12 US US17/174,826 patent/US11542264B2/en active Active
- 2021-02-25 ZA ZA2021/01273A patent/ZA202101273B/en unknown
- 2021-03-03 EC ECSENADI202114902A patent/ECSP21014902A/es unknown
- 2021-03-03 CO CONC2021/0002898A patent/CO2021002898A2/es unknown
-
2023
- 2023-07-13 US US18/221,694 patent/US20240199617A1/en active Pending
- 2023-08-02 CY CY20231100387T patent/CY1126144T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA49971A (fr) | Vésicules extracellulaires modifiées et leurs utilisations | |
MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA53351A (fr) | Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
MA50502A (fr) | Adénovirus et utilisations associées | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
MA42665A (fr) | Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations | |
MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
MA55083A (fr) | Polyribonucléotides et leurs utilisations cosmétiques | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
MA49398A (fr) | Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci |